Diabetes is a chronic condition. Since many of the symptoms of diabetes mellitus are reversible, many people can control their blood sugar adequately with proper nutrition and regular exercise.
Diabetes is probably a family trait. There is no evidence for environmental triggers in development of the disease. It may, however, be modulated by genetics.
Diabetes has its roots in a progressive deterioration of the functions of many body organs including the brain. Diabetes is the underlying cause for many neuropathic and ischemic complications of vascular disease, which leads to the deterioration of one's own brain.
Most patients with diabetes are treated for their condition; however, there are also other treatments that are typically implemented in diabetics. Some of these include, but are not limited to, antihypertensive medications, oral medication for hypertension and insulin, and oral medication for controlling glucose levels or lowering cholesterol in diabetics.
Symptoms of diabetes mellitus include frequent urination, excessive thirst, fatigue and headaches. In addition there is a loss of skin sensation and increased skin pigmentation. A person with diabetes mellitus may not realize the significance of these symptoms. Diabetes can be prevented and managed by regular screening and the detection of early signs of disease.
Diabetes was fairly common in US adults. More than one-third (36.0%) of US adults received a diabetes diagnosis in the 12-month or prior period, and about one in four (23.6%) had been diagnosed in the past 6 months. Women and Latinos had higher prevalence of diabetes in comparison to Caucasians (17.4% vs. 10.2%, respectively). Among adults with diabetes, the most common treatment regimen (monotherapy) was metformin (51.0%), and combination medication was the second most common regimen (37.8%).
Although clopidogrel is an antiplatelet drug, it also acts directly on thrombin to prevent clot formation in the arterial system. This mechanism seems to be associated with how clopidogrel reduces the risk of thromboembolism when used during pregnancy and in patients who undergo surgery. Clopidogrel may also be an effective anticoagulant during treatment of type 2 diabetes.
Trial eligibility based on age and HbA1c was more accurate than clinical assessment for the presence of diabetes and was associated with greater treatment intensity. Thus, this clinical assessment, while helpful to identify potential trial candidates, was not as reliable or accurate as trial eligibility. Trial eligibility as an indication for potential participation increased treatment intensity both by identifying individuals who would benefit from a trial and by identifying individuals who were undertreated.
The present study demonstrated that patients on dual antiplatelet treatment with two or more clopidogrel-containing agents are more likely to suffer a myocardial infarction than patients receiving an anticoagulant with a nonanatomic chemical in a similar category as clopidogrel; therefore, care must be taken when performing cardiac and cerebrovascular imaging with these combinations of antiplatelet therapies.
A number of new drug approaches have been invented that have the potential to have an all new role in the treatment of the diabetes mellitus. Although most of them are in the early phases of clinical trials it is hoped that new medicines may be available sooner or later in more forms of treating the diseases to the diabetic patients in the near future.
Clopidogrel and aspirin appear to be potentially interchangeable in people, at least in the short term after PCI. If, after 2 years, you have high on-treatment platelet reactivity (HTPR), further data are needed to determine whether clopidogrel, with the possibility of being an alternative, could be useful.
The diabetes-specific mortality risk is increased in all persons with diabetes compared with non-diabetes, but with a stronger association in persons with the more severe disease. This disparity is partly attributed to differences in comorbidity between the two cohorts.